

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 September 2004 (23.09.2004)

PCT

(10) International Publication Number
WO 2004/080421 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number:
PCT/US2004/007606

(22) International Filing Date: 12 March 2004 (12.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/454,125 12 March 2003 (12.03.2003) US

(71) Applicant (for all designated States except US):
PHARMA MAR, S.A. [ES/ES]; Calle de la Calera,
3, Poligono Industrial de Tres Cantos, E-28760 Tres
Cantos (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARNEJEE, De-**
babrata [US/—]. **BERTINO, Joseph, R.** [US/—]. **FAIR-**
CLOTH, Glynn, Thomas [US/—]. **GURAY, Saydam.**
JIMENO, Jose [ES/—].

(74) Agent: **MYERS, Louis**; Fish & Richardson P.C., 225
Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **IMPROVED ANTITUMORAL TREATMENTS**

(57) Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.

WO 2004/080421 A2

THIS PAGE BLANK (USPTO)


IMPROVED ANTITUMORAL TREATMENTS

FIELD OF THE INVENTION

The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of leukemias and lymphomas.

BACKGROUND OF THE INVENTION

Aplidine (Dehydrodidemnin B) is a cyclic depsipeptide that was isolated from a Mediterranean marine tunicate, *Aplidium albicans*, and it is the subject of WO 9109485. It is related to compounds known as didemnins, and has the following structure:



More information on aplidine, aplidine analogues, their uses, formulations and synthesis can be found in patent applications WO 98 1352, WO 99 42125, WO 01 76616, WO 01 35974, WO 02 30441 and WO 02 02596. We incorporate by specific reference the content of each of these PCT texts.

In both animal and human preclinical studies and in clinical Phase I studies this agent has been shown to have cytotoxic potential against a broad spectrum of tumor types including leukemia and lymphoma. See for example :

Faircloth, G. *et al.*: "Dehydrodidemnin B (DDB) a new marine derived anticancer agent with activity against experimental tumour models", 9th NCI-EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 111;

Faircloth, G. *et al.*: "Preclinical characterization of aplidine, a new marine anticancer depsipeptide", *Proc Amer Assoc Cancer Res* 1997, 38: Abst 692;

Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR.: "In vitro activity of Aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells" *Br. J. Cancer*, 1998; 78: 739-744;

Faircloth G, Grant W, Nam S, Jimeno J, Manzanares I, Rinehart K.: "Schedule-dependency of Aplidine, a marine depsipeptide with antitumor activity", *Proc. Am. Assoc. Cancer Res.* 1999; 40: 394;

Broggini M, Marchini S, D'Incalci M, Taraboletti G, Giavazzi R, Faircloth G, Jimeno J.: "Aplidine blocks VEGF secretion and VEGF/VEGF-R1 autocrine loop in a human leukemic cell line", *Clin Cancer Res* 2000; 6 (suppl): 4509;

Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, Vignati S, Codegoni A, Desiderio MA, Faircloth G, Jimeno J and D'Incalci M.: "Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine", *Br J Cancer* 2002; 86: 1510-1517;

Paz-Ares L, Anthony A, Pronk L, Twelves C, Alonso S, Cortes-Funes H, Celli N, Gomez C, Lopez-Lazaro L, Guzman C, Jimeno J, Kaye S.: "Phase I clinical and pharmacokinetic study of aplidine, a new marine didemnin, administered as 24-hour infusion weekly" *Clin. Cancer Res.* 2000; 6 (suppl): 4509;

Raymond E, Ady-Vago N, Baudin E, Ribrag V, Faivre S, Lecot F, Wright T, Lopez Lazaro L, Guzman C, Jimeno J, Ducreux M, Le Chevalier T, Armand JP.: "A phase I and pharmacokinetic study of aplidine given as a 24-hour continuous infusion every other week in patients with solid tumor and lymphoma", *Clin. Cancer Res.* 2000; 6 (suppl): 4510;

Maroun J, Belanger K, Seymour L, Soulieres D, Charpentier D, Goel R, Stewart D, Tomiak E, Jimeno J, Matthews S. : "Phase I study of aplidine in a 5 day bolus q 3 weeks in patients with solid tumors and lymphomas", *Clin. Cancer Res.* 2000; 6 (suppl): 4509;

Izquierdo MA, Bowman A, Martinez M, Cicchella B, Jimeno J, Guzman C, Germa J, Smyth J.: "Phase I trial of Aplidine given as a 1 hour intravenous weekly infusion in patients with advanced solid tumors and lymphoma", *Clin. Cancer Res.* 2000; 6 (suppl): 4509.

Mechanistic studies indicate that aplidine can block VEGF secretion in ALL-MOLT4 cells and in vitro cytotoxic activity at low concentrations (5nM) has been observed in AML and ALL samples from pediatric patients with de novo or relapsed ALL and AML. Aplidine appears to induce both a G1 and a G2 arrest in drug treated leukemia cells in vitro. Apart from down regulation of the VEGF receptor, little else is known about the mode(s) of action of aplidine.

In phase I clinical studies with aplidine, L-carnitine was given as a 24 hour pretreatment or co-administered to prevent myelotoxicity, see for example WO 02 30441. Co-administration of L-carnitine was proven to be able to improve the recovery of the drug induced muscular toxicity and has allowed for dose escalation of aplidine.

Thus in clinical Phase I studies aplidine was not myelotoxic at maximum tolerated doses, except for mild lymphopenia. These characteristics make aplidine a potentially useful agent for the

treatment of leukemia. Adding aplidine to the current chemotherapy for leukemia could improve efficacy without the necessity of dose reductions of drugs with proven antileukemic activity, because of increased myelotoxicity. This seems especially relevant for the treatment of relapsed ALL and newly diagnosed and relapsed AML, since these are diseases with a relatively poor prognosis, which are currently being treated with myelotoxic drug combinations.

SUMMARY OF THE INVENTION

We have for the first time established that aplidine and aplidine analogues potentiate other anticancer agents and therefore can be successfully used in combination therapy for the treatment of cancer. This invention is directed to pharmaceutical compositions, pharmaceutical dosage forms, kits and methods for the treatment of cancer using these combination therapies.

In accordance with one aspect of this invention, we provide effective combination therapies based on aplidine and aplidine analogues, using other drugs which are effective in the treatment of cancer. Preferably the other drug is effective in the treatment of leukemia and/or lymphoma. Most preferably the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.

In another embodiment the invention encompasses a method of treating primary and/or metastatic cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of aplidine or an aplidine analogue, or a pharmaceutically acceptable prodrug, salt, solvate or hydrate thereof, and a therapeutically effective

amount of another drug which is effective in the treatment of cancer or a pharmaceutically acceptable prodrug, salt, solvate or hydrate thereof, administered prior, during, or after administering aplidine or aplidine analogue.

Preferably the other drug is effective in the treatment of leukemia and/or lymphoma. Most preferably the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin. The other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or at a different time.

The cancer to be treated is preferably a leukemia or a lymphoma, most preferably ALL, AML, CML, MML or CLL.

In another aspect the invention encompasses a method of increasing the therapeutic efficacy of a drug effective in the treatment of cancer, preferably a drug effective in the treatment of leukemia and/or lymphoma, most preferably a drug selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin, or a pharmaceutically acceptable prodrug, salt, solvate or hydrate thereof, which comprises administering to a patient in need thereof an amount of aplidine or an aplidine analogue, or a pharmaceutically acceptable prodrug, salt, solvate or hydrate thereof. Aplidine or the aplidine analogue is administered prior, during, or after administering the other drug.

Aplidine or an aplidine analogue is able to increase the therapeutic efficacy of some cancer drugs. In one aspect, the result is synergism, rather than additive. Such synergistic combinations represent a preferred aspect of the present invention. Synergism may

be indicated by use of the Chou-Talalay method, or other methods. In other instances, antagonism may be found.

In a further aspect the invention encompasses a pharmaceutical composition comprising aplidine or an aplidine analogue, or a pharmaceutically acceptable prodrug, salt, solvate or hydrate thereof, and another drug effective in the treatment of cancer. Preferably the other drug is effective in the treatment of leukemia and/or lymphoma. Most preferably the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.

The invention also encompasses a kit for use in the treatment or prevention of cancer which comprises a dosage form of aplidine or an aplidine analogue, or a pharmaceutically acceptable prodrug, salt, solvate or hydrate thereof, a dosage form of another drug effective in the treatment of cancer, or a pharmaceutically acceptable prodrug, salt, solvate or hydrate thereof, and instructions for the use of each actor in combination for the treatment or prevention of cancer. Preferably the other drug is effective in the treatment of leukemia and/or lymphoma. Most preferably the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.

In a further aspect, the invention is directed to the use of aplidine for the treatment of chronic lymphocytic leukemia.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. Aplidine inhibits growth of CLL cells in culture

- Fig. 2.** Aplidine is a potent inhibitor of preB-ALL cells in culture
- Fig. 3.** The cytotoxic dose-response curve of CCRF-CEM (Fig. 3A), SKI-DLCL (Fig. 3B) and K562 (3C) cells following aplidine treatment for 96 hours
- Fig. 4.** Chou-Talalay analysis of combination of aplidine and AraC in CCRF-CEM cells
- Fig. 5.** Chou-Talalay analysis of combination of aplidine and AraC in SKI-DLCL cells
- Fig. 6.** Chou-Talalay analysis of combination of aplidine and mitoxantrone in CCRF-CEM cells
- Fig. 7.** Chou-Talalay analysis of combination of aplidine and mitoxantrone in SKI-DLCL cells
-
- Fig. 8.** Chou-Talalay analysis of combination of aplidine and methotrexate in CCRF-CEM cells
- Fig. 9.** Chou-Talalay analysis of combination of aplidine and doxorubicin in CCRF-CEM cells
- Fig. 10.** Chou-Talalay analysis of combination of aplidine and vinblastine in CCRF-CEM cells
- Fig. 11.** Chou-Talalay analysis of combination of aplidine and doxorubicin in SKI-DLCL cells
- Fig. 12.** Chou-Talalay analysis of combination of aplidine and vinblastine in SKI-DLCL cells
- Fig. 13.** Chou-Talalay analysis of combination of aplidine and methylprednisolone in SKI-DLCL cells
- Fig. 14.** Combination of IC₂₀ of aplidine lowered the IC₅₀ of AraC in CCRF-CEM (Fig. 12A) and SKI-DLCL (Fig. 12B) cells after incubation for 96 hours
- Fig. 15.** The effect of aplidine on *in vivo* tumor size as a single agent and in combination with AraC

DETAILED DESCRIPTION OF THE INVENTION

By cancer it is meant to include tumors, neoplasias, and any other malignant tissue or cells. The present invention is directed to the use of aplidine or an aplidine analogue in combination for the treatments of cancer in general, but more preferably for the treatment of different leukemias and lymphomas.

In order to study the possible potentiation of other anticancer agents with aplidine we have initiated a systematic study of drug combinations for possible use in leukemias and lymphomas. Aplidine was found to be an effective *in vitro* cytotoxic agent against primary cells from a patient with preB-ALL (DM4) as well as against fresh cells obtained from six chronic lymphocytic leukemia (CLL) patients. The IC₅₀ value was 10 nM for 3 day exposure with the DM4 line and after a 11 day exposure with the primary CLL samples.

Drug combination studies were carried out on established cell lines rather than primary cells. We studied three cell lines viz. K562, CCRF-CEM and SKI-DLCL representing acute myeloid leukemia, lymphoblastic lymphoma and diffuse B cell large cell lymphoma respectively. The data in the examples show that Aplidine potentiates the effect of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone as well as doxorubicin in K562, CCRF-CEM and SKI-DLCL cells by lowering the IC₅₀s for the drugs.

Thus we have found that aplidine is a potent cytotoxic agent against cells of several hematologic malignancies. Significantly, we have established for the first time that aplidine inhibits growth of CLL cells in culture. We also found that aplidine enhances the cytotoxicity of agents used in the treatment of leukemias, such as methotrexate

(MTX), cytosine arabinoside (AraC), mitoxantrone (Mitox), vinblastine (Vinb), methylprednisolone (Metpred) and doxorubicin (DOX).

Leukemia is classified by how quickly it progresses. Acute leukemia is fast-growing and can overrun the body within a few weeks or months. By contrast, chronic leukemia is slow-growing and progressively worsens over years.

The blood-forming (hematopoietic) cells of acute leukemia remain in an immature state, so they reproduce and accumulate very rapidly. Therefore, acute leukemia needs to be treated immediately, otherwise the disease may be fatal within a few months. Fortunately, some subtypes of acute leukemia respond to available therapies and they are curable. Children often develop acute forms of leukemia, which are managed differently from leukemia in adults.

In chronic leukemia, the blood-forming cells eventually mature, or differentiate, but they are not "normal". They remain in the bloodstream much longer than normal white blood cells, and they are unable to combat infection well.

Leukemia also is classified according to the type of white blood cell that is multiplying - that is, lymphocytes (immune system cells), granulocytes (bacteria-destroying cells), or monocytes (macrophage-forming cells). If the abnormal white blood cells are primarily granulocytes or monocytes, the leukemia is categorized as myelogenous, or myeloid, leukemia. On the other hand, if the abnormal blood cells arise from bone marrow lymphocytes, the cancer is called lymphocytic leukemia.

Other cancers, known as lymphomas, develop from lymphocytes within the lymph nodes, spleen, and other organs. Such cancers do not originate in the bone marrow and have a biological behavior that is different from lymphocytic leukemia.

There are over a dozen different types of leukemia, but four types occur most frequently. These classifications are based upon whether the leukemia is acute versus chronic and myelogenous versus lymphocytic, that is:

Acute myelogenous leukemia (AML): also known as acute nonlymphocytic leukemia (ANLL) - is the most common form of adult leukemia. Most patients are of retirement age (average age at diagnosis = 65 years), and more men are affected than women. Fortunately, because of recent advances in treatment, AML can be kept in remission (lessening of the disease) in approximately 60% to 70% of adults who undergo appropriate therapy. Initial response rates are approximately 65-75% but the overall cure rates are more on the order of 40-50%.

Chronic myelogenous leukemia (CML) is known as a myeloproliferative disorder - that is, it is a disease in which bone marrow cells proliferate (multiply) outside of the bone marrow tissue. CML is easy to diagnose, since it has a genetic peculiarity, or marker, that is readily identifiable under a microscope. About 95% of CML patients have a genetic translocation between chromosomes 9 and 22 in their leukemic cells. The Philadelphia chromosome causes uncontrolled reproduction and proliferation of all types of white blood cells and platelets (blood clotting factors). CML is not yet curable by standard methods of chemotherapy or immunotherapy.

Acute lymphocytic leukemia (ALL) - also known as acute lymphoblastic leukemia - is a malignant disease caused by the abnormal growth and development of early nongranular white blood cells, or lymphocytes. The leukemia originates in the blast cells of the bone marrow (B-cells), thymus (T-cells), and lymph nodes. ALL occurs predominantly in children, peaking at 4 years of age.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in North America and in Europe. It is a disease of older adults and is very rare among people who are younger than 50 years of age. Men with CLL outnumber women by a 2-to-1 average. CLL is thought to result from the gradual accumulation of mature, long-lived lymphocytes. Therefore, this cancer is caused not so much by overgrowth as it is by the extreme longevity and build-up of malignant cells. Although the rate of accumulation varies among individuals, the extensive tumor burden eventually causes complications in all CLL patients.

The compositions of the present invention may comprise both components (drugs) in a single pharmaceutically acceptable formulation. Alternatively, the components may be formulated separately and administered in combination with one another. Various pharmaceutically acceptable formulations well known to those of skill in the art can be used in the present invention. Selection of an appropriate formulation for use in the present invention can be performed routinely by those skilled in the art based upon the mode of administration and the solubility characteristics of the components of the composition.

Examples of pharmaceutical compositions containing Aplidine or an aplidine analogue include liquid (solutions, suspensions or emulsions) with suitable composition for intravenous administration, and they may contain the pure compound or in combination with any carrier or other pharmacologically active compounds. Solubilised aplidine shows substantial degradation under heat and light stress testing conditions, and a lyophilised dosage form was developed, see W099/42125 incorporated herein by reference.

Administration of aplidine or compositions of the present invention is based on a Dosing Protocol preferably by intravenous

infusion. We prefer that infusion times of up to 72 hours are used, more preferably 1 to 24 hours, with about 1, about 3 or about 24 hours most preferred. Short infusion times which allow treatment to be carried out without an overnight stay in hospital are especially desirable. However, infusion may be around 24 hours or even longer if required. Infusion may be carried out at suitable intervals with varying patterns, illustratively once a week, twice a week, or more frequently per week, repeated each week optionally with gaps of typically one week.

The correct dosage of the compounds of the combination will vary according to the particular formulation, the mode of application, and the particular situs, host and tumour being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account. Administration can be carried out continuously or periodically within the maximum tolerated dose. Further guidance for the administration of aplidine is given in WO 0135974 which is incorporated herein by reference in its entirety.

For the present invention, analogues of aplidine can be used in place of APL, aplidine itself. Typically such compounds are as defined in WO 0202596. Examples of compounds for the present invention include the preferred compounds given in WO 0202596, and in particular we import into this patent specification the discussion of preferred compounds and related aspects given in WO 0202596. More preferably, the analogues are structurally close to aplidine, and usually differ from aplidine in respect of one amino acid or the terminal sidechain. The different amino acid can be in the cyclic part of the molecule or in the sidechain. Many examples of such compounds are

given in WO 0202596, and they are candidates for use in the present invention.

EXAMPLES

EXAMPLE 1

Aplidine was tested against various primary cells from patients with hematologic malignancies. The cells used were:

- fresh cells obtained from six chronic lymphocytic leukemia patients
- primary cell from a patient with preB-ALL (DM4)

Patient samples were obtained with prior consent and CLL cells were isolated by density gradient centrifugation over histopaque. The media used was RPMI supplemented with 10% autologous serum and L-glutamine. The cultures were incubated with 10 nM aplidine and cell viability was measured days 3, 7, 11 and 18 and compared with viability of untreated cells and STI 571 (0.5mM).

The results of these studies are shown in figures 1-2.

Example 2

In order to study the possible potentiation of other anticancer agents we undertook a study of drug combinations for possible use in leukemias and lymphomas.

Drug combination studies were carried out on established cell lines rather than primary cells. We studied three cell lines, viz. K562 as a model for acute myeloid leukemia, CEM representing acute lymphocytic leukemia and SKI-DLCL representing diffuse large cell

lymphoma. Combination studies with IC₂₀ and IC₅₀ dose of aplidine with a dose range of methotrexate, cytosine arabinoside and doxorubicin were tested to determine if aplidine could potentiate the effect of these drugs.

The results are shown in table 1:

Additional Drug	IC ₅₀ Dox	IC ₅₀ MTX	IC ₅₀ Ara-C
No Aplidine	18 nM	5nM	30 nM
IC ₂₀ Aplidine (0.5nM)	1 nM	500pM	6nM

p<0.01, p<0.05, p<0.05

Clearly, these data show that aplidine potentiates the effect of doxorubicin, methotrexate and cytosine arabinoside by lowering very significantly the IC₅₀s for the drugs.

Example 3: In vitro studies to determine the effect of aplidine as a single agent on CCRF-CEM, SKI-DLCL and K562 cell lines.

CCRF-CEMS, SKI-DLCL and K562 cells are maintained in RPMI 1640 supplemented with 10%FCS. To determine the cytotoxic effect of aplidine on all cell lines and to obtain the IC₅₀ of aplidine in these cell lines, cells were plated into 96 well plates and incubated for 96 hours in humidified and 5%CO₂ containing incubator. Cell viability is measured by XTT assay in an automated plate reader. We found aplidine to be cytotoxic to all cell lines with an IC₅₀ dose of 0.5-1.0 nM (figure 3).

Example 4: Studies on in vitro effect of aplidine + drug combination with fixed doses of IC₅₀:IC₅₀ on all cell lines.

Methotrexate, cytosine arabinoside C (ara-C), mitoxantrone, methylprednisolone, vinblastine and doxorubicin were tested in combination with aplidine.

Chou-Talalay analysis was used to analyze the drug combinations. When Combination Index (CI) obtained by this analysis is less than 1, the drugs are synergistic; when CI is 1, the drugs are additive; and, if CI is greater than 1, the drugs are antagonistic.

All the cytotoxicity studies were performed by using XTT or MTS. We first determined the IC₅₀ dose of these drugs in SKI-DLCL, CCRF-CEM and K562 cell lines. We investigated drug combinations using IC₅₀(Aplidine):IC₅₀(DrugX) fixed ratio.

In table 2 is shown the combination of aplidine and Ara-C with the dose of (IC₅₀:IC₅₀) in CCRF-CEM cells.

Table 2

Ratio	Dose of APL	Dose of AraC	Viability (% of control)
Control	0	0	100
IC ₅₀ (APL)	0.5 nM	0	52.7
IC ₅₀ (AraC)	0	10 nM	56.4
x16	8 nM	160 nM	4.7
x8	4 nM	80 nM	7.9
x4	2 nM	40 nM	7.6
x2	1 nM	20 nM	7.8
IC ₅₀ :IC ₅₀	0.5 nM	10 nM	10.6
x 1/2	0.25 nM	5 nM	16.2
x 1/4	1.125 nM	2.5 nM	36.7
x 1/8	0.0625 nM	1.25 nM	70.8

The results of Chou-Talalay analysis of combination of aplidine and Ara-C in CCRF-CEM cells can be seen in figure 4. The CI for this combination in CCRF-CEM cells is 0.469.

In table 3 is shown the combination of aplidine and Ara-C with the dose of (IC₅₀:IC₅₀) in SKI-DLCL cells.

Table 3

Ratio	Dose of APL	Dose of AraC	Viability (% of control)
Control	0	0	100
IC ₅₀ (APL)	0.5 nM	0	50
IC ₅₀ (AraC)	0	30 nM	50
x16	8 nM	480 nM	12
x8	4 nM	240 nM	10.7
x4	2 nM	120 nM	14.1
x2	1 nM	60 nM	17.4
IC ₅₀ :IC ₅₀	0.5 nM	30 nM	23.1
x 1/2	0.25 nM	15 nM	25.4
x 1/4	1.125 nM	7.5 nM	25.5
x 1/8	0.0625 nM	3.75 nM	50.8

The results of Chou-Talalay analysis of combination of aplidine and Ara-C in SKI-DLCL cells can be seen in figure 5. The CI for this combination in SKI-DLCL cells is 0.306.

In table 4 is shown the combination of aplidine and Ara-C with the dose of (IC₅₀:IC₅₀) in K562 cells.

Ratio	Dose of APL	Dose of AraC	Viability (% of control)
Control	0	0	100

IC50(APL)	1 nM	0	50
IC50(AraC)	0	30 nM	50
x16	16 nM	480 nM	11.8
x8	8 nM	240 nM	15.2
x4	4 nM	120 nM	15.5
x2	2 nM	60 nM	17
IC50:IC50	1 nM	30 nM	22.1
x 1/2	0.5 nM	15 nM	25.6
x 1/4	0.25nM	7.5 nM	31.1
x 1/8	0.125 nM	3.75 nM	44.2

The CI for this combination in K562 cells is 0.502.

In table 5 is shown the combination of aplidine and mitoxantrone with the dose of (IC₅₀:IC₅₀) in CCRF-CEM cells.

Ratio	Dose of APL	Dose of Mitoxantrone	Viability (% of control)
Control	0	0	100
IC50(APL)	0.5 nM	0	50
IC50(Mitox)	0	30 nM	56
x16	8 nM	480 nM	9.9
x8	4 nM	240 nM	11.6
x4	2 nM	120 nM	11.9
x2	1 nM	60 nM	13.8
IC50:IC50	0.5 nM	30 nM	20.6
x 1/2	0.25 nM	15 nM	39.7
x 1/4	1.125 nM	7.5 nM	60.7
x 1/8	0.0625 nM	3.75 nM	76.5

The results of Chou-Talalay analysis of combination of aplidine and mitoxantrone in CCRF-CEM cells can be seen in figure 6. The CI for this combination in CCRF-CEM cells is 0.911.

In table 6 is shown the combination of aplidine and mitoxantrone with the dose of (IC₅₀:IC₅₀) in SKI-DLCL cells.

	Dose of APL	Dose of Mitoxantrone	Viability (% of control)
Control	0	0	100
IC ₅₀ (APL)	0.5 nM	0	50
IC ₅₀ (Mitox)	0	5 nM	50
x16	8 nM	80 nM	17
x8	4 nM	40 nM	29
x4	2 nM	20 nM	22.6
x2	1 nM	10 nM	19.9
IC ₅₀ :IC ₅₀	0.5 nM	5 nM	32.2
x 1/2	0.25 nM	2.5 nM	53.1
x 1/4	1.125 nM	1.25 nM	58.6
x 1/8	0.0625 nM	0.625 nM	70.1

The results of Chou-Talalay analysis of combination of aplidine and mitoxantrone in SKI-DLCL cells can be seen in figure 7. The CI for this combination in SKI-DLCL cells is 0.646.

In table 7 is shown the combination of aplidine and mitoxantrone with the dose of (IC₅₀:IC₅₀) in K562cells.

	Dose of APL	Dose of Mitoxantrone	Viability (% of control)
Control	0	0	100
IC ₅₀ (APL)	1 nM	0	50
IC ₅₀ (Mitox)	0	7.5 nM	50.7
x16	16 nM	120 nM	9.9
x8	8 nM	60 nM	11.6

x4	4 nM	30 nM	11.9
x2	2 nM	15 nM	13.8
IC ₅₀ :IC ₅₀	1 nM	7.5 nM	20.6
x 1/2	0.5 nM	3.75 nM	39.7
x 1/4	0.25nM	1.8 nM	60.7
x 1/8	0.125 nM	0.9 nM	76.5

The CI for this combination in K562 cells is 0.487.

In table 8 is shown the combination of alidine and mthotrexate with the dose of (IC₅₀:IC₅₀) in CCRF-CEM cells.

Ratio	Dose of APL	Dose of Metotrexate	Viability (% of control)
Control	0	0	100
IC ₅₀ (APL)	0.5 nM	0	50
IC ₅₀ (MTX)	0	10 nM	50
x16	8 nM	160 nM	5
x8	4 nM	80 nM	13
x4	2 nM	40 nM	11
x2	1 nM	20 nM	12
IC ₅₀ :IC ₅₀	0.5 nM	10 nM	20
x 1/2	0.25 nM	5 nM	30
x 1/4	1.125 nM	2.5 nM	88
x 1/8	0.0625 nM	1.25 nM	100

The results of Chou-Talalay analysis of combination of alidine and mthotrexate in CCRF-CEM cells can be seen in figure 8. The CI for this combination in CCRF-CEM cells is 0.950.

The results of Chou-Talalay analysis of combination of aplidine and Doxorubicin in CCRF-CEM cells can be seen in figure 9. The CI for this combination in CCRF-CEM cells is 1.952.

The results of Chou-Talalay analysis of combination of Aplidine and vnbilastine in CCRF-CEM cells can be seen in figure 10. The CI for this combination in CCRF-CEM cells is 2.046.

In table 9 is shown the combination of alidine and dxorubicin with the dose of (IC₅₀:IC₅₀) in SKI-DLCL cells.

Ratio	Dose of APL	Dose of Doxorubicin	Viability (% of control)
Control	0	0	100
IC ₅₀ (APL)	0.5 nM	0	50
IC ₅₀ (Doxo)	0	5 nM	50
x16	8 nM	80 nM	9.4
x8	4 nM	40 nM	8.6
x4	2 nM	20 nM	8
x2	1 nM	10 nM	9.7
IC ₅₀ :IC ₅₀	0.5 nM	5 nM	21
x 1/2	0.25 nM	2.5 nM	40
x 1/4	1.125 nM	1.25 nM	45
x 1/8	0.0625 nM	0.625 nM	49

The results of Chou-Talalay analysis of combination of alidine and dxorubicin in SKI-DLCL cells can be seen in figure 11. The CI for this combination in SKI-DLCL cells is 0.478.

In table 10 is shown the combination of alidine and vnbilastine with the dose of (IC₅₀:IC₅₀) in SKI-DLCL cells.

Ratio	Dose of APL	Dose of Vinblastine	Viability (% of control)
Control	0	0	100
IC ₅₀ (APL)	0.5 nM	0	50
IC ₅₀ (Vnb)	0	4 nM	50

x16	8 nM	64 nM	15
x8	4 nM	32 nM	17
x4	2 nM	16 nM	17
x2	1 nM	8 nM	21
IC50:IC50	0.5 nM	4 nM	29
x 1/2	0.25 nM	2 nM	25
x 1/4	1.125 nM	1 nM	28
x 1/8	0.0625 nM	0.5 nM	38

The results of Chou-Talalay analysis of combination of alidine and vnbastine in SKI-DLCL cells can be seen in figure 12. The CI for this combination in SKI-DLCL cells is 0.760.

In table 11 is shown the combination of alidine and methylprednisolone with the dose of (IC₅₀:IC₅₀) in SKI-DLCL cells.

	Dose of APL	Dose of methylprednisolone	Viability (% of control)
Control	0	0	100
IC50(APL)	0.5 nM	0	50
IC50(Metpred)	0	160 nM	51
x16	8 nM	2560 nM	10.8
x8	4 nM	1280 nM	17.3
x4	2 nM	640 nM	16.7
x2	1 nM	320 nM	17.4
IC50:IC50	0.5 nM	160 nM	24.7
x 1/2	0.25 nM	80 nM	32.4
x 1/4	1.125 nM	40 nM	39.1
x 1/8	0.0625 nM	20 nM	50

The results of Chou-Talalay analysis of combination of alidine and methylprednisolone in SKI-DLCL cells can be seen in figure 13. The CI for this combination in SKI-DLCL cells is 0.646.

Example 5.

We have also investigated the cytotoxic effect of combination of IC₂₀ (APL) with a variable dose of AraC on CCRF-CEM and SKI-DLCL cell lines. Aplidine in both cell lines potentiated the effect of AraC, the IC₅₀ dose of AraC was reduced from 30 nM to 1.6 nM in SKI-DLCL cell line, and from 10 nM to 0.8 nM in CCRF-CEM cell line respectively (figure 14). Data was obtained after cell incubation for 96 hours and using XTT assay. The results represent means of three different experiments.

Example 6. *In vivo* studies.

We have performed *in vivo* experiments to study the effect of alidine alone and in combination with other drugs for lymphoid malignancies.

Determination of maximum tolerated dose (MTD) in C.B.-17 *scid/scid* (SCID mice)

We have used an *in vivo* model of human lymphoma in SCID mice for this purpose. Specifically, we have used CCRF-CEMS cells and CB.17 *scid/scid* mice. We have experience with this model and have evaluated drug treatments using this xenograft (Lacerda J.F. *et al.* Blood 85 (10): 2675-2679 (1995)). We found that a total dose of 1

mg/kg/ week given in five daily doses is the aplidine maximum dose that can be tolerated by mice.

Determination of in vivo antitumor effect of alidine as a single agent and in combination with AraC in SCID mice xenograft model

SCID mice were inoculated subcutaneously in the right flank with 10^7 CEM-T leukemic cells. They were observed twice weekly for tumor formation at the site of inoculation. After establishment of palpable tumor, alidine was injected as single agent and in combination with several doses of AraC to determine the antitumor effect. Mice were randomized to receive alidine alone at doses of 0.75 mg/kg and 1 mg/kg, AraC alone at 50 mg/kg, or combination of Aplidine and AraC for all dose combinations. The AraC dose chosen for this combination is the dose at which the tumor growth was inhibited but no tumor regression occurred. All drugs were administered intra-peritoneally, and tumor size was compared to a control group of mice not receiving any treatment and for combination groups, compared to tumor sizes with single agent treatment.

The most effective combination was found to be AraC-50 mg/kg + alidine-0.75 mg/kg (figure 15).

These findings in respect of aplidine can be extended to aplidine analogues, derivatives and related compounds. For example, the present invention provides a combination of a compound such as those of WO 02 02596 with an anticancer drug, preferably an anti-leukemia drug or anti-lymphoma drug, notably methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone or doxorubicin.

CLAIMS

1. Use of aplidine or an aplidine analogue in the manufacture of a medicament for the treatment of primary and/or metastatic cancer by combination therapy employing aplidine or an aplidine analogue with another drug.
2. The use of aplidine or an aplidine analogue according to claim 1, wherein the cancer to be treated is a leukemia or a lymphoma.
3. The use of aplidine or an aplidine analogue according to any of the preceding claims, wherein the aplidine or the aplidine analogue and the other drug form part of the same medicament.
4. The use of aplidine or an aplidine analogue according to any of claims 1 to 3 wherein the aplidine or the aplidine analogue and the other drug are provided as separate medicaments for administration at the same time or at different times.
5. The use of aplidine or an aplidine analogue according to any of the preceding claims, wherein the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.

6. The use of aplidine or an aplidine analogue according to any of the preceding claims, wherein the aplidine or the aplidine analogue is aplidine.
7. A method of treating primary and/or metastatic cancer comprising administering to a patient in need of such treatment a ~~therapeutically effective amount of aplidine or an analogue of~~ aplidine and a therapeutically effective amount of another drug which is effective in the treatment of cancer, administered prior, during, or after administering the aplidine or the aplidine analogue.
8. The method of treating primary and/or metastatic cancer according to claim 6, wherein the cancer to be treated is a leukemia or a lymphoma.
9. The method of treating primary and/or metastatic cancer according to claim 7 or 8, wherein the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.
10. A method of increasing the therapeutic efficacy of a drug effective in the treatment of cancer, which comprises administering to a patient in need thereof an amount of aplidine or an analogue of aplidine, the aplidine or the analogue of aplidine being administered prior, during, or after administering the other drug.

11. The method of increasing the therapeutic efficacy of a drug effective in the treatment of cancer according to claim 10, wherein the cancer to be treated is a leukemia or a lymphoma.
12. The method of increasing the therapeutic efficacy of a drug effective in the treatment of cancer according to claims 10 or 11, wherein the drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.
13. A pharmaceutical composition comprising aplidine or an aplidine analogue and another drug effective in the treatment of cancer.
14. The pharmaceutical composition according to claim 13, wherein the other drug is effective in the treatment of a leukemia and/or a lymphoma.
15. The pharmaceutical composition according to any of claims 13 or 14, wherein the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.
16. A kit for use in the treatment or prevention of cancer which comprises a dosage form of aplidine or an aplidine analogue, a dosage form of another drug effective in the treatment of cancer and

instructions for the use of each actor in combination for the treatment or prevention of cancer.


17. The kit according to claim 16, wherein the kit is for use in the treatment or prevention of a leukemia and/or a lymphoma.

18. The kit according to any of claims 16 or 17, wherein the other drug is selected from the group consisting of methotrexate, cytosine arabinoside, mitoxantrone, vinblastine, methylprednisolone and doxorubicin.

19. A use of aplidine or an aplidine analogue in the manufacture of a medicament for the treatment of chronic lymphocytic leukaemia.


THIS PAGE BLANK (USPTO)

1/15

**Figure 1**

THIS PAGE BLANK (USPTO)

2/15

**Figure 2**

THIS PAGE BLANK (USPTO)

3/15




Figure 3A (CCRF-CEM)




Figure 3B (SKI-DLCL)




Figure 3C (K562)

Figure 3

THIS PAGE BLANK (USPTO)

4/15






Figure 4



THIS PAGE BLANK (USPTO)

5/15

**Figure 5**

THIS PAGE BLANK (USPTO)

6/15

**Figure 6**

THIS PAGE BLANK (USPTO)

7/15







Figure 7


THIS PAGE BLANK (USPTO)

8/15

**Figure 8**

THIS PAGE BLANK (USPTO)

9/15

**Figure 9**

THIS PAGE BLANK (USPTO)

10/15





Figure 10

THIS PAGE BLANK (USPTO)

11/15







Figure 11



THIS PAGE BLANK (USPTO)

12/15

**Figure 12**

THIS PAGE BLANK (USPTO)

13/15

**Figure 13**

THIS PAGE BLANK (USPTO)

14/15




Figure 14A





Figure 14B

Figure 14

THIS PAGE BLANK (USPTO)

15/15

**Figure 15**

THIS PAGE BLANK (USPTO)